MTOR and cancer: Our dataset, which is restricted to luminal cancers, demonstrated that pAKT pathway activation is associated with luminal A/PIK3CA mutations and good prognosis, while p-mTOR/pS6 is not, suggesting that the presence of HER2 and basal subtype in the primary analysis of the TCGA masked these observations.